Une nouvelle génération d’immunothérapies ciblant la voie CD39/CD73/adénosine pour favoriser la réponse immunitaire anti-tumorale

Laurent Gros, Carine Paturel, Ivan Perrot, Armand Bensussan, Jean-François Eliaou, Jérémy Bastid, Nathalie Bonnefoy

Open source

DOI: 10.1051/medsci/2020006
Published: 2020-02
Container: médecine/sciences
Publisher: EDP Sciences
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1051/medsci/2020006,
  title = {Une nouvelle génération d’immunothérapies ciblant la voie CD39/CD73/adénosine pour favoriser la réponse immunitaire anti-tumorale},
  author = {Laurent Gros and Carine Paturel and Ivan Perrot and Armand Bensussan and Jean-François Eliaou and Jérémy Bastid and Nathalie Bonnefoy},
  year = {2020},
  journal = {médecine/sciences},
  doi = {10.1051/medsci/2020006},
  url = {https://doi.org/10.1051/medsci/2020006}
}

RIS

TY  - JOUR
TI  - Une nouvelle génération d’immunothérapies ciblant la voie CD39/CD73/adénosine pour favoriser la réponse immunitaire anti-tumorale
AU  - Laurent Gros
AU  - Carine Paturel
AU  - Ivan Perrot
AU  - Armand Bensussan
AU  - Jean-François Eliaou
AU  - Jérémy Bastid
AU  - Nathalie Bonnefoy
PY  - 2020
JO  - médecine/sciences
DO  - 10.1051/medsci/2020006
UR  - https://doi.org/10.1051/medsci/2020006
ER  -

APA

Gros, L., Paturel, C., Perrot, I., Bensussan, A., Eliaou, J., Bastid, J., & Bonnefoy, N. (2020). Une nouvelle génération d’immunothérapies ciblant la voie CD39/CD73/adénosine pour favoriser la réponse immunitaire anti-tumorale. médecine/sciences. https://doi.org/10.1051/medsci/2020006

Source records

crossref · retrieved 2026-09-26T10:49:54.731Z